Charles Schwab Investment Management Inc. Sells 6,758 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Charles Schwab Investment Management Inc. trimmed its stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 2.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 269,654 shares of the company’s stock after selling 6,758 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Kodiak Sciences were worth $2,683,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in KOD. US Bancorp DE purchased a new stake in Kodiak Sciences during the fourth quarter valued at $40,000. Bank of New York Mellon Corp increased its position in shares of Kodiak Sciences by 5.3% during the 4th quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company’s stock valued at $976,000 after purchasing an additional 4,927 shares during the last quarter. Peapod Lane Capital LLC purchased a new stake in shares of Kodiak Sciences during the 4th quarter valued at about $1,660,000. SG Americas Securities LLC lifted its stake in shares of Kodiak Sciences by 61.4% in the 4th quarter. SG Americas Securities LLC now owns 20,684 shares of the company’s stock worth $206,000 after purchasing an additional 7,871 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Kodiak Sciences by 220.9% in the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock worth $117,000 after buying an additional 30,735 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Stock Up 1.7 %

NASDAQ KOD opened at $3.06 on Friday. Kodiak Sciences Inc. has a 52 week low of $2.19 and a 52 week high of $11.60. The company has a market capitalization of $161.03 million, a P/E ratio of -0.84 and a beta of 2.26. The stock’s 50-day moving average price is $4.93 and its 200-day moving average price is $5.40.

Kodiak Sciences (NASDAQ:KOD) last released its earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.06. Research analysts anticipate that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Analysts Set New Price Targets

Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Monday, December 9th.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.